Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Poster Presentations to Focus on Reqorsa as a Potential Treatment for Ras Inhibitor Resistant Lung Cancer, Mesothelioma and Glioblastoma
海報展示將重點介紹Reqorsa作爲Ras抑制劑耐藥性肺癌、間皮瘤和膠質母細胞瘤的潛在治療方法
AUSTIN, Texas, Sept. 9, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators were selected to present at the upcoming 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held October 23-25, 2024 in Barcelona, Spain. The collaborators will present posters on positive preclinical data from studies of its lead drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), for the treatment of Ras inhibitor resistant lung cancer, mesothelioma and glioblastoma.
德克薩斯州奧斯汀，2024 年 9 月 9 日 /PRNewswire/ — Genprex, Inc.（「Genprex」 或 「公司」）（納斯達克： GNPX）是一家臨床階段的基因療法公司，專注於爲癌症和糖尿病患者開發改變生活的療法。該公司今天宣佈，其研究合作者被選中出席即將於2024年10月23日至25日在西班牙巴塞羅那舉行的2024年EORTC-NCI-AACR分子靶標和癌症治療研討會。合作者將展示其用於治療Ras抑制劑耐藥肺癌、間皮瘤和膠質母細胞瘤的主要候選藥物Reqorsa基因療法（quaratusugene ozeplasmid）研究的積極臨床前數據的海報。
"We are very pleased that these studies with our academic partners have been selected for presentation, which expands the growing body of preclinical evidence supporting REQORSA's potential to treat a variety of cancers," said Ryan Confer, President and Chief Executive Officer at Genprex. "We look forward to these presentations next month which will share the compelling data that support the potential for new clinical studies evaluating Reqorsa as a potential treatment for additional types of lung cancer, mesothelioma and glioblastoma."
Genprex總裁兼首席執行官瑞安·康弗表示：「我們很高興與我們的學術合作伙伴合作開展的這些研究被選中進行展示，這擴大了越來越多的臨床前證據，支持REQORSA治療各種癌症的潛力。」「我們期待下個月的這些演講，這些演講將分享令人信服的數據，這些數據支持評估Reqorsa作爲其他類型肺癌、間皮瘤和膠質母細胞瘤潛在治療方法的新臨床研究的潛力。」
Featured Genprex-supported posters to be presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics include:
將在2024 年 EORTC-NCI-AACR 分子靶標和癌症治療研討會上展出的由 GenPrex 支持的精選海報包括：
Title: "TUSC2 gene therapy in KRASG12C mutant NSCLC overcomes acquired resistance to sotorasib"
Collaborator: The University of Texas MD Anderson Cancer Center
Catalog Number: 384
Presentation Number: PB372
標題：「KRASG12C 突變體 NSCLC 中的 TUSC2 基因療法克服了對索托拉西布的獲得性耐藥性」
合作者：德克薩斯大學醫學博士安德森癌症中心
目錄號：384
演示編號：PB372
Title: "TUSC2 Suppresses Tumorigenic Properties in Malignant Pleural Mesothelioma Cells"
Collaborator: New York University Langone Health
Catalog Number: 364
Presentation Number: PB352
標題：「TUSC2 抑制惡性胸膜間皮瘤細胞的致瘤特性」
合作者：紐約大學朗格尼健康
目錄號：364
演示編號：PB352
Title: "Efficacy of Quaratusugene Ozeplasmid TUSC2 Gene Therapy in Glioblastoma"
Collaborator: The University of Texas Health Science Center at Houston
Catalog Number: 130
Presentation Number: PB118
標題：「Quaratusgene Ozeplasmid TUSC2 基因療法在膠質母細胞瘤中的療效」
合作者：休斯敦德克薩斯大學健康科學中心
目錄號：130
演示編號：PB118
Genprex has filed two provisional patent applications based on data from two of the presentations. One application involves using REQORSA to treat mesothelioma and the other to treating glioblastoma. Genprex is a co-owner of the applications along with the respective institutions. TUSC2 is the tumor suppressor gene used in REQORSA. REQORSA consists of a TUSC2 gene expressing plasmid encapsulated in non-viral lipid-based nanoparticles in a lipoplex form (the Company's Oncoprex Delivery System), which has a positive charge. REQORSA is injected intravenously and specifically targets cancer cells. REQORSA is designed to deliver the functioning TUSC2 gene to negatively charged cancer cells while minimizing uptake by normal tissue. Laboratory studies conducted at MD Anderson show that the uptake of TUSC2 in tumor cells in vitro after REQORSA treatment was 10 to 33 times the uptake in normal cells.
Genprex根據其中兩次演示的數據提交了兩份臨時專利申請。一種應用涉及使用REQORSA治療間皮瘤，另一種用於治療膠質母細胞瘤。Genprex是應用程序的共同所有者，也是相應機構的共同所有者。TUSC2 是 REQORSA 中使用的腫瘤抑制基因。REQORSA 由一種表達質粒的 TUSC2 基因組成，質粒封裝在非病毒脂基納米顆粒中，呈脂質體形式（該公司的Oncoprex輸送系統），該質粒具有正電荷。REQORSA 通過靜脈注射，專門靶向癌細胞。REQORSA 旨在將功能正常的 TUSC2 基因傳遞給帶負電荷的癌細胞，同時最大限度地減少正常組織的吸收。在 MD Anderson 進行的實驗室研究表明，REQORSA 治療後腫瘤細胞體外吸收 TUSC2 是正常細胞攝取量的 10 到 33 倍。
About Genprex, Inc.
關於 Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
Genprex, Inc. 是一家臨床階段的基因療法公司，專注於爲癌症和糖尿病患者開發改變生活的療法。Genprex的技術旨在管理抗病基因，爲目前治療選擇有限的大量癌症和糖尿病患者群體提供新療法。Genprex與世界一流的機構和合作者合作，開發候選藥物，以進一步發展其基因療法產品線，從而提供新的治療方法。Genprex的腫瘤學項目利用其全身性非病毒Oncoprex輸送系統，該系統使用脂質基納米顆粒以脂質形式封裝表達基因的質粒。所得產物通過靜脈注射，由腫瘤細胞吸收，然後腫瘤細胞表達腫瘤中缺乏的腫瘤抑制蛋白。該公司的主要候選產品Reqorsa基因療法（quaratusugene ozeplasmid）正在兩項臨床試驗中作爲非小細胞肺癌和小細胞肺癌的治療方法接受評估。Genprex的每項肺癌臨床項目都獲得了美國食品藥品管理局頒發的用於治療該患者群體的快速通道稱號，而Genprex的SCLC計劃已獲得美國食品藥品管理局孤兒藥稱號。Genprex的糖尿病基因治療方法由一種新的輸液過程組成，該過程使用AAV載體將Pdx1和mafA基因直接輸送到胰腺。在 1 型糖尿病模型中，GPX-002 將胰腺中的 α 細胞轉化爲功能性 β 樣細胞，這些細胞可以產生胰島素，但可能與 β 細胞截然不同，足以逃避人體的免疫系統。採用類似的方法，用於不起自身免疫作用的 2 型糖尿病的 GPX-002 被認爲可以恢復活力並補充耗盡的 β 細胞。
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.
鼓勵感興趣的投資者和股東通過訪問公司網站、註冊電子郵件提醒以及在推特、Facebook和LinkedIn上關注Genprex來註冊新聞稿和行業最新動態。
Cautionary Language Concerning Forward-Looking Statements
關於前瞻性陳述的警示性語言
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.
本新聞稿中有關非歷史事實事項的陳述是1995年《私人證券訴訟改革法》所指的 「前瞻性陳述」。這些前瞻性陳述是根據管理層當前的信念、預期和假設做出的，不能保證業績，並且存在重大風險和不確定性。因此，應根據各種重要因素來考慮這些前瞻性陳述，包括Genprex不時向美國證券交易委員會提交併應審查的報告中列出的那些因素，包括Genprex截至2023年12月31日止年度的10-K表年度報告中 「第1A項——風險因素」 下的陳述。
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.
由於前瞻性陳述受風險和不確定性的影響，因此實際結果可能與此類前瞻性陳述所表達或暗示的結果存在重大差異。此類聲明包括但不限於以下方面的聲明：Genprex根據預計的時間表和規格推進其候選產品的臨床開發、製造和商業化的能力；Genprex臨床試驗和監管批准的時機和成功；Genprex的候選產品，單獨或與其他療法聯合使用對癌症和糖尿病的影響；任何戰略研發優先計劃以及任何其他任何其他療法的影響戰略選擇或其他Genprex爲優化和重新調整Genprex的糖尿病、腫瘤學和/或其他臨床開發項目而採取的或將來可能採取的努力，包括資源的優先順序，以及Genprex能夠在多大程度上成功實施此類努力和舉措以實現預期和預期的結果；Genprex的未來增長和財務狀況，包括Genprex保持遵守納斯達克資本市場持續上市要求的能力，以及繼續作爲持續經營企業然後獲取資金，以可接受的條件或完全滿足其長期流動性需求；Genprex的商業和戰略合作伙伴關係，包括與第三方供應商、供應商和製造商的合作伙伴關係，以及他們成功進行和擴大候選產品製造規模的能力；以及Genprex的知識產權和許可證。
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
不應將這些前瞻性陳述作爲對未來事件的預測，Genprex無法向您保證這些陳述中討論或反映的事件或情況將會實現或將會發生。如果事實證明此類前瞻性陳述不準確，則不準確性可能是重大的。您不應將這些聲明視爲Genprex或任何其他人對Genprex將在任何特定時間範圍內實現其目標和計劃的陳述或保證，或者根本不是。提醒您不要過分依賴這些前瞻性陳述，這些陳述僅代表截至本新聞稿發佈之日。除非法律要求，否則Genprex不承擔在本新聞稿發佈之日後公開更新或發佈對這些前瞻性陳述的任何修訂的義務，無論是由於新信息、未來事件還是其他原因造成的，或者是爲了反映意外事件的發生。
Genprex, Inc.
(877) 774-GNPX (4679)
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
[email protected]
GNPX 投資者關係
[電子郵件保護]
GNPX Media Contact
Kalyn Dabbs
[email protected]
GNPX 媒體聯繫人
Kalyn Dabbs
[電子郵件保護]
SOURCE Genprex, Inc.
來源 Genprex, Inc.
譯文內容由第三人軟體翻譯。